Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)

A legfontosabb adatok

Ki végzi
Tortugas Neuroscience, Inc.
Hol
Ausztrália és Új-Zéland10 helyszín, 2 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
100 fő, tervezett
Kezdés
2026. okt. 14.
Várható befejezés
2027. aug.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • TRTL-913
  • Placebo
A regiszteradat frissítve
2026. november 4.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 39 feltétel megnézéseKevesebb

Ki vehet részt

  • Part A Inclusion Criteria:
  • Healthy male or female adults aged 18 to 64 years (or 65 to 80 years for an elderly cohort, if enrolled), as determined by the investigator
  • Able and willing to provide written informed consent and comply with all study procedures
  • Body mass index (BMI) 18.0 to 35.0 kilograms per square meter (kg/m\^2) and body weight greater than (>) 50 kilogram (kg)
  • Clinically acceptable medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead ECG, as determined by the investigator
  • QT interval corrected using the Fridericia method (QTcF) of less than or equal to (≤) 450 millisecond (msec) for males or ≤470 msec for females
  • Nonsmokers or light smokers (<10 cigarettes/week or equivalent vaping) for at least 3 months before dosing and willing to abstain during confinement
  • Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period
  • Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period; Part B Inclusion Criteria:
  • Male or female adults aged 18 to 64 years
  • Able and willing to provide written informed consent and comply with study procedures
  • Diagnosis of subjective, stable, chronic, non-pulsatile tinnitus
  • Generally healthy aside from tinnitus, with no clinically significant abnormalities on medical history, physical or neurologic examination, vital signs, laboratory tests, or ECG that would interfere with study participation
  • BMI 18.0 to 35.0 kg/m\^2 and body weight >50 kg
  • Willing to discontinue prohibited medications and substances before study treatment and throughout study participation
  • Women of childbearing potential must have a negative pregnancy test and agree to use highly effective contraception throughout the required study period
  • Male participants must agree to use appropriate contraception and refrain from sperm donation for the required study period

Ki nem vehet részt

  • Use of prohibited medications, including moderate or strong cytochrome (CY)P450 inhibitors or inducers, or other prohibited foods or supplements before dosing
  • Use of prohibited medications, including moderate or strong CYP450 inhibitors or inducers, or other prohibited foods or supplements before dosing
  • Any clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments
  • History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk
  • Active infection or clinically significant recent illness before screening or dosing
  • Positive test for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
  • History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ)
  • Current or recent substance or alcohol use disorder or positive drug or alcohol screening
  • Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk
  • History of seizures, epilepsy, significant head injury associated with loss of consciousness, or other conditions or medications that increase seizure risk
  • Clinically significant acute or chronic medical condition that, in the investigator's opinion, could affect participant safety or study assessments
  • Positive test for HIV, hepatitis B, or hepatitis C
  • History of malignancy within the past 10 years (except adequately treated nonmelanoma skin cancer or cervical carcinoma in situ)
  • Current or recent substance or alcohol use disorder or positive drug or alcohol screening
  • Current or history of clinically significant psychiatric illness or suicidal ideation or behavior that would increase study risk
  • Clinically significant cardiovascular disease, clinically significant ECG abnormalities, long QT syndrome, torsade de pointes, or a family history of long QT syndrome or sudden cardiac death
  • Clinically significant hepatic or renal impairment or clinically significant laboratory abnormalities
  • Part A Exclusion Criteria:
  • Pregnant, breastfeeding, or planning pregnancy during the study; Part B Exclusion Criteria:
  • Current use of, or plans to initiate, pharmacologic or non-pharmacologic treatment for tinnitus during the study
  • Regular night-shift work that could interfere with study assessments
  • Pregnant, breastfeeding, or planning pregnancy during the study

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Új-Zéland.

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.

A vizsgálat 3 csoportja

  • Part A: Multiple Ascending Doses of TRTL-913A vizsgált kezelés

    Participants will receive TRTL-913 immediate-release capsules administered once daily (QD) on Day 1 through Day 7.

    Kezelés: TRTL-913

  • Part A: PlaceboPlacebo, összehasonlításként

    Participants will receive TRTL-913 matching placebo administered QD on Day 1 through Day 7.

    Kezelés: Placebo

  • Part B: TRTL-913A vizsgált kezelés

    Participants will self-administer TRTL-913 immediate-release capsules QD on Day 1 through Day 14. Additional doses will be based on the results from Part A.

    Kezelés: TRTL-913

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2a, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TRTL-913 in Healthy Adult Volunteers Under Fed Conditions (Part A), and an Open-Label Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy in Adults With Tinnitus (Part B)
Kérdések a feltételekről
Forrás: NCT07777549: ki vehet részt
A regiszteradat frissítve
2026. november 4.